No Data
Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH): The company did not repurchase shares in June.
On June 2024, Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) announced that it did not repurchase any shares. As of June 30, 2024, the company has accumulated repurchased 1,228,955 shares of the company through Shanghai Stock Exchange trading system in a centralized bidding trading manner, accounting for 0.4479% of the total share capital of 274,400,000 shares, with a highest repurchase price of 9.24 yuan per share and a lowest repurchase price of 5.45 yuan per share. The total amount paid for this repurchase is RMB 7,997,384.37 (excluding transaction fees such as stamp duty and trading commission).
Nucien Pharma Completes Phase 2 Trials for Influenza Drug
Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) disclosed the results of Phase II clinical trial of inhaled ribavirin solution.
Hunan Nucien Pharmaceutical Co. Ltd. (688189.SH) has announced that its in-progress project, Paramivir Inhalation Solution, has recently been completed.
Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) has repurchased a cumulative total of 0.4479% of its shares.
On June 3rd, Gelunhui reported that as of May 31st, 2024, Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) had accumulated the repurchase of 1,228,955 shares of the company's stock through the Shanghai Stock Exchange trading system in a centralized auction trading manner, accounting for 0.4479% of the total share capital of the company of 274,400,000 shares. The highest transaction price of the repurchase was 9.24 yuan/share, the lowest was 5.45 yuan/share, and the total amount of funds paid was RMB 7,997,384.37 yuan (excluding transaction fees such as stamp duty and transaction commission).
Nanxin Pharmaceutical (688189.SH): The company did not repurchase shares in April
Gelonghui, May 7, 丨 Nanxin Pharmaceutical (688189.SH) announced that in April 2024, the company did not repurchase shares. As of April 30, 2024, the company has repurchased a total of 1,228,955 shares through the Shanghai Stock Exchange trading system, accounting for 0.4479% of the company's total share capital of 274,400,000 shares. The highest price of the repurchase transaction was 9.24 yuan/share, the lowest price was 5.45 yuan/share, and the total capital paid was RMB 7,997,384.37 (excluding transaction fees such as stamp duty and transaction commissions).
Nanxin Pharmaceutical (688189.SH) announced first-quarter results, net profit of 37.6665 million yuan, a decrease of 69.95%
Nanxin Pharmaceutical (688189.SH) released its report for the first quarter of 2024, achieving operating income of 1.1 during the reporting period...
Hunan Nucien Pharmaceutical Co., Ltd. (SHSE:688189) May Have Run Too Fast Too Soon With Recent 29% Price PlummetNo Data
